Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Is Ribavirin Teratogenic in Humans? No Evidence So Far.

Literature DB >> 28913820

Is Ribavirin Teratogenic in Humans? No Evidence So Far.

Vicente Soriano^1,2, Pablo Barreiro^3,4.

Abstract

Entities: Chemical Species

Mesh：

Substances：

Year: 2017 PMID： 28913820 DOI： 10.1007/s40264-017-0597-z

Source DB: PubMed Journal: Drug Saf ISSN： 0114-5916 Impact factor: 5.606

× No keyword cloud information.

16 in total

1. No evidence for mutagenic effects of ribavirin: report of two normal pregnancies.

Authors: K Hegenbarth; U Maurer; P M Kroisel; P Fickert; M Trauner; R E Stauber
Journal: Am J Gastroenterol Date: 2001-07 Impact factor: 10.864

2. Conception soon after discontinuing interferon/ribavirin therapy: a successful outcome.

Authors: D Mishkin; M Deschênes
Journal: Am J Gastroenterol Date: 2001-07 Impact factor: 10.864

3. Paternal exposure to ribavirin: pregnancy and neonatal outcome.

Authors: Marco De Santis; Brigida Carducci; Anna Franca Cavaliere; Lidia De Santis; Angela Lucchese; Gianluca Straface; Alessandro Caruso
Journal: Antivir Ther Date: 2003-02

4. Impact of ITPA gene polymorphisms on the risk of ribavirin-induced haemolytic anaemia using interferon-free antivirals for chronic hepatitis C.

Authors: Isabella Esposito; Laura Benítez-Gutiérrez; Ana Treviño; Ana Arias; Maria Jesus Citores; Silvia Requena; Vicente Soriano; Valentín Cuervas-Mons; Carmen de Mendoza
Journal: Antivir Ther Date: 2017-02-15

5. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypes.

Authors: Susanna Naggie; Norma I Rallon; José M Benito; Judith Morello; Sonia Rodriguez-Novoa; Paul J Clark; Alexander J Thompson; Kevin V Shianna; Eugenia Vispo; John G McHutchison; David B Goldstein; Vincent Soriano
Journal: J Infect Dis Date: 2011-12-09 Impact factor: 5.226

6. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients.

Authors: W C Maddrey
Journal: Semin Liver Dis Date: 1999 Impact factor: 6.115

7. Impact of inosine triphosphatase gene variants on the risk of anemia in HIV/hepatitis C virus-coinfected patients treated for chronic hepatitis C.

Authors: Norma I Rallón; Judit Morello; Pablo Labarga; José M Benito; Sonia Rodríguez-Nóvoa; Eugenia Vispo; Pablo Barreiro; M Ángeles Castro; Koldo Aguirrebengoa; Juan A Pineda; P Miralles; M Jesús Tellez; Joaquín Portu; Celia Miralles; Antonio Ocampo; Vincent Soriano
Journal: Clin Infect Dis Date: 2011-10-25 Impact factor: 9.079

8. Infant of 22 months of age with no anomalies born from a HCV- and HIV-infected mother under treatment with pegylated interferon, ribavirin and antiretroviral therapy during the first 16 weeks of pregnancy.

Authors: Pablo Labarga; Javier Pinilla; Iban Cachorro; Yolanda Ruiz; Yolanda Ruiz del Prado
Journal: Reprod Toxicol Date: 2007-07-07 Impact factor: 3.143